Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis

Questions: Discounts, Updates etc.

Pages: 250

Price (Single): $3995

Price (Departmental):

Price (Company):

Publication Date: 2008-11-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.  Several promising vaccines including the propholactic Gardasil have created a pathway for new vaccine products. M-Vax and OncoVax, in late stage development are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products. Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patient-by-patient basis. This report provides a realistic estimate of the cancer vaccine for the near term for the following products:

As part of its exhaustive research and analysis, this report provides:

Some of the issues discussed in this report important for anyone operating in this market include:

As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

 

CHAPTER TWO: INTRODUCTION
Introduction
History and Growth of the Cancer Treatment Market
Types of Vaccines
Antigen/Adjuvant Vaccines
Whole Cell Tumor Vaccines
Dendritic Cell (DC) Vaccines
Viral Vectors and DNA Vaccines
Idiotype Vaccines
Types of Therapeutic Vaccines
Patient-Specific Vaccines
Prostate Specific Antigen
Sialyl Tn
Heat Shock Proteins
Ganglioside Molecules
Carcinoembryonic Antigen (CEA)
MART-1
Tyrosinase
Adjuvants
Industry Structure
Demographics and Statistics
Growing and Aging Population
Life Expectancy and Cancer

 

CHAPTER THREE: CERVICAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Gardasil/Silgard
Cervarix
Description of Vaccines in Development
TG 4001/R3484
HspE7
Lovaxin C
VGX-3100
CA-9
Market Summary
Current and Potential Competitors and Analysis, 2012

 

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
Overview
Description of Vaccines on the Market
OncoVAX
Description of Vaccines in Development
OncoVAX
TroVAX
Avicine
CEA VRP Vaccine
Collidem
IMA910
Lapuleucel-T
Oncophage
CDX-1307-01
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2012

 

CHAPTER FIVE: LUNG CANCER VACCINES
Overview
Description of Vaccines in Development
Lucanix
MAGE-A3 Peptide
Stimuvax
EGF Cancer Vaccine
GV-1001
HyperAcute Lung
IDM 2101 (EP-2101)
Oncophage
INGN 225
TG 4010
LungVAX
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
DC Vax
L523S
Market Summary
Potential Competitors and Analysis, 2012

 

CHAPTER SIX: LYMPHOMA VACCINES
Overview
Description of Vaccines in Development
MyVax
BiovaxID
FavId
TG 1042
Market Summary
Potential Competitors and Analysis, 2012

 

CHAPTER SEVEN: MELANOMA VACCINES
Overview
Description of Vaccines on the Market
Description of Vaccines in Development
M-VAX
GMK
Allovectin-7
MDX-1379 with Combination Treatment MDX-010
Oncophage
MAGE-A3 ASCI 3
Uvidem
AGI-101H Vaccine
ALVAC Vaccine
HyperAcute Melanoma
Market Summary
Potential Competitors and Analysis, 2012

 

CHAPTER EIGHT: PROSTATE CANCER VACCINES
Overview
Description of Vaccines in Development
Provenge
DCVax-Prostate
GVAX
ProstAtak
TroVAX
Telomerase Cancer Vaccine
MVA-BN Prostate
HyperAcute Prostate
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2012

 

CHAPTER NINE: BREAST CANCER VACCINES
Overview
Description of Vaccines in Development
INGN 225
CEA VRP Vaccine
MVA-BN HER2
Lapuleucel-T
PX 104.1
CDX-1307-02
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary

 

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
Overview
Description of Vaccines in Development
GV 1001
GI-4000
Avicine
GVAX
HyperAcute Pancreas
Oncophage
CDX-1307-01
CRS-100
CRS-207
DC Vax
MKC1106-PP
Market Summary

 

CHAPTER ELEVEN: RENAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Oncophage
Description of Vaccines in Development
Oncophage
Reniale
TroVAX
IMA901
AGS-003
MDX-1106
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2012

 

CHAPTER TWELVE: BRAIN CANCER VACCINES
Overview
Glioblastoma
Neuroblastoma
Description of Vaccines in Development
DCVax-Brain
CDX-110
GliAtak
Oncophage
Market Summary

 

CHAPTER THIRTEEN: BLADDER CANCER VACCINES
Overview
Description of Vaccines on the Market
BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-Shire Pharmaceuticals)
Description of Vaccines in Development
Bexidem
CG0070
MDX-1307-01
Market Summary

 

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
Overview
Description of Vaccines in Development
OVax Autologous Cell Vaccine
Lapuleucel-T
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary

 

CHAPTER FIFTEEN: LEUKEMIA VACCINES
Overview
Description of Vaccines in Development
GVAX
PR1 Peptide Vaccine
AGS-005
Market Summary

 

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Introduction
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Political and Social Pressure
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
New Genetic Technique
Future Growth in Vaccines

 

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS
Overview
Total Market Size and Forecast
Market and Competitor Analysis

 

CHAPTER EIGHTEEN: CANCER VACCINE CORPORATE PROFILES
Introduction
Antigenics, Inc
Avax Technologies, Inc
Biovest International, Inc
Cell Genesys, Inc
Dendreon Corporation
Genitope Corporation
GlaxoSmithKline plc
Merck & Company, Inc
Northwest Biotherapeutics, Inc
NovaRx
Oncothyreon
Vaccinogen
Vical, Inc

 

CHAPTER NINETEEN: COMPANY NAMES AND ADDRESSES

 

Tables & Figures
CHAPTER ONE: EXECUTIVE SUMMARY
  • Table 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
  • Figure 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
CHAPTER TWO: INTRODUCTION
  • Table 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
  • Figure 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
  • Table 2-2: Total Cancer Incidence by Sex and Country, 2007 Estimates
  • Figure 2-2: Total Cancer Incidence by Sex and Country
  • Table 2-3: World Population by Selected Geographical Region, 2007-2050
  • Figure 2-4: World Population by Selected Geographical Region, 2007-2050
  • Table 2-4: Estimated World Population by Age and Geographical Region, 2007
  • Figure 2-4: Estimated World Population by Age and Geographical Region, 2007
  • Table 2-5: Percent Population Over 65 by Year and Region
  • Figure 2-5: Estimated World Population by Age, 2007 and 2050
  • Table 2-6: Life Expectancy at Birth by Selected Countries, 2006
  • Table 2-6: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
  • Table 2-7: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004

 

CHAPTER THREE: CERVICAL CANCER VACCINES
  • Table 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
  • Figure 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
  • Table 3-2: Cervical Cancer Vaccines Approved and in the Pipeline
  • Table 3-3: The Developing Cervical Cancer Vaccine Market, 2008-2012
  • Figure 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012
  • Table 3-4: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 3-3: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 3-4: Anticipated Product Sales by Year for Cervical Cancer Vaccines, 2008-2012

 

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
  • Table 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
  • Figure 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
  • Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline
  • Table 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
  • Figure 4-2: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
  • Figure 4-3: Anticipated Product Sales by Year for Emerging Colon/Rectal Cancer Vaccines, 2008-2012

 

CHAPTER FIVE: LUNG CANCER VACCINES
  • Table 5-1: Types of Primary Lung Cancer
  • Table 5-2: Estimated World Incidence of Lung Cancer by Country, 2007
  • Figure 5-1: Estimated World Incidence of Lung Cancer by Country, 2007
  • Table 5-3: Lung Cancer Vaccines in the Pipeline

 

CHAPTER SIX: LYMPHOMA VACCINES
  • Table 6-1: Classification of Non-Hodgkin’s Lymphomas
  • Table 6-2: Estimated World Incidence of Lymphoma by Country, 2007
  • Figure 6-1: Estimated World Incidence of Lymphoma by Country, 2007
  • Table 6-3: Lymphoma Vaccines in the Pipeline
  • Table 6-4: The Emerging Lymphoma Vaccine Market, 2008-2012
  • Figure 6-2: The Emerging Lymphoma Vaccine Market, 2008-2012
  • Table 6-5: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 6-3: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 2010-2012

 

CHAPTER SEVEN: MELANOMA VACCINES
  • Table 7-1: Malignant Condidtions of the Skin
  • Table 7-2: Estimated World Incidence of Melanoma by Country, 2007
  • Figure 7-1: Estimated World Incidence of Melanoma by Country, 2007
  • Table 7-3: Melanoma Vaccines in the Pipeline
  • Table 7-4: The Developing Melanoma Vaccine Market, 2008-2012
  • Figure 7-2: The Developing Melanoma Vaccine Market, 2008-2012
  • Table 7-5: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 7-3: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 7-4:Anticipated Product Sales by Year for Developing Melanoma Vaccines, 2010-2012

 

CHAPTER EIGHT: PROSTATE CANCER VACCINES
  • Table 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
  • Figure 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
  • Table 8-2: Prostate Cancer Vaccines in the Pipeline
  • Table 8-3: The Emerging Prostate Cancer Vaccine Market, 2008-2012
  • Figure 8-2: The Emerging Prostate Cancer Vaccine Market, 2008-2012
  • Table 8-4: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 8-3: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 8-4: Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2012

 

CHAPTER NINE: BREAST CANCER VACCINES
  • Table 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
  • Figure 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
  • Table 9-2: Breast Cancer Vaccines in the Pipeline

 

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
  • Table 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
  • Figure 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
  • Table 10-2: Gastrointestinal Cancer Vaccines in the Pipeline

 

CHAPTER ELEVEN: RENAL CANCER VACCINES
  • Table 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
  • Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
  • Table 11-2: Renal Cancer Vaccines in the Pipeline
  • Table 11-3: The Developing Renal Cancer Vaccine Market, 2008-2012
  • Figure 11-2: The Developing Renal Cancer Vaccine Market, 2008-2012
  • Table 11-4: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 11-3: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 11-4: Anticipated Product Sales by Year for Renal Cancer Vaccines, 2008-2012

 

CHAPTER TWELVE: BRAIN CANCER VACCINES
  • Table 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
  • Figure 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
  • Table 12-2: Brain Cancer Vaccines in the Pipeline

 

CHAPTER THIRTEEN: BLADDER CANCER VACCINES
  • Table 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
  • Figure 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
  • Table 13-2: Bladder Cancer Vaccines in the Pipeline

 

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
  • Table 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
  • Figure 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
  • Table 14-2: Ovarian Cancer Vaccines in the Pipeline

 

CHAPTER FIFETEEN: LEUKEMIA VACCINES
  • Table 15-1: TYPES OF LEUKEMIA
  • Table 15-2: Estimated World Incidence of Leukemia by Country, 2007
  • Figure 15-1: Estimated World Incidence of Leukemia Cancer by Country, 2007
  • Table 15-3: Leukemia Vaccines in the Pipeline

 

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
  • Table 16-1: Cancer Detection Tests

 

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS
  • Table 17-1: Cancer Vaccines: Developing and Emerging Cancer VaccineMarkets, 2008-2012
  • Figure 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
  • Figure 17-2: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2012

 

CANCER VACCINE CORPORATE PROFILES

 

COMPANY NAMES AND ADDRESSES

Other users found this report page using the following search terms: Cancer Vaccine M-VAX GMK Allovectin MDX-1379 MDX-010 Oncophage MAGE Uvidem cancer market vaccine vaccines ovarian pipeline emerging oncotice lung 2008

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.